Tofacitinib for Down Syndrome

(MISSION-1 Trial)

This trial tests tofacitinib, a medication that may help treat Down syndrome by blocking certain enzymes (Janus kinases) that affect the body's immune system. Researchers aim to determine the treatment's safety and effectiveness over six months. Participants will receive either the medication or a placebo (a harmless pill for comparison), and those in the placebo group might later try the actual treatment. This trial suits individuals with Down syndrome who weigh at least 10 kilograms and have not previously used similar treatments. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

You may need to stop taking certain medications to participate in this trial. Specifically, you cannot use other immunosuppressants, strong CYP3A4 inhibitors or inducers, or certain other medications that might interfere with the study drug. It's best to discuss your current medications with the study team to see if any changes are needed.

Studies have shown that tofacitinib is generally well-tolerated in people with Down syndrome. In one study, the first 10 participants experienced significant improvements without serious side effects. The most common side effects were mild, such as headaches and diarrhea. Additionally, the FDA has already approved tofacitinib for other conditions, which supports its safety profile. However, more research is needed to fully understand its long-term safety in people with Down syndrome.¹²³⁴⁵

Most treatments for Down syndrome focus on managing symptoms and improving quality of life through therapies and educational support. However, tofacitinib is unique because it directly targets the biological processes associated with Down syndrome. Tofacitinib works by inhibiting enzymes called JAK1 and JAK3, which are involved in immune system signaling. This mechanism could potentially address underlying issues in Down syndrome, offering a more targeted approach than current management strategies. Researchers are excited about the potential of tofacitinib to provide more comprehensive benefits beyond symptom management.

This trial will evaluate the safety and efficacy of tofacitinib for individuals with Down syndrome. Studies have shown that tofacitinib, a type of medication, can improve autoimmune conditions in this population. Research indicates that this medication reduces inflammation by lowering certain immune system markers. For instance, it has balanced inflammation levels and benefited skin conditions related to the immune system. Some patients with Down syndrome demonstrated better understanding and task completion after using tofacitinib. While it doesn't completely stop the immune response, it reduces the immune system's overactivity, which is promising for treating various conditions in Down syndrome. Participants in this trial will receive either tofacitinib or a placebo to assess these effects.¹²⁴⁶⁷